Lilly’s Zepbound shows promise in teen obesity trial
ljubaphoto/E+ via Getty Images
Eli Lilly’s (LLY) Zepbound helped adolescents with obesity or excess weight and related health conditions achieve substantial weight reductions in a new study, supporting the company’s push to expand the medicine’s use to younger patients.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.